B and BIOA-B.ST Related Headlines
Go Back- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Leqembi® approved for the treatment of early Alzheimer's disease in Australia
- BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- Leqembi® (lecanemab) launched in the EU today
- Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
B and BIOA-B.ST Related Press Releases
Go Back- Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
- Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
- New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment
- Invitation to presentation of BioArctic's third quarter report for July - September 2025 on November 13 at 9.30 a.m. CET
- Health Canada Grants Authorization for Leqembi® (lecanemab)
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- Leqembi® approved for the treatment of early Alzheimer's disease in Australia
- BioArctic: Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
- Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer's disease under Fast Track status
- Leqembi® (lecanemab) launched in the EU today
- Invitation to presentation of BioArctic's second quarter report for April - June 2025 on August 28 at 9.30 a.m. CET
- BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
- BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
